Jane Henderson, Chief Financial Officer at Apogee Therapeutics, Inc. (APGE), sold 2,000 shares at $81.02 ($164K) on 2026-05-01, disclosed to the SEC on 2026-05-04.
Scheduled sale ($164k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $81.02 | 811 | $66K | 40.0% |
| 2 | $82.60 | 900 | $74K | 45.3% |
| 3 | $83.16 | 289 | $24K | 14.6% |
| Total | $82.04 avg | 2,000 | $164K | 100% |
| Filing → |
| APGE | SELL | 2026-03-27 | $170K | — | Filing → |
| APGE | SELL | 2026-03-04 | $140K | — | Filing → |
| APGE | SELL | 2026-02-04 | $132K | — | Filing → |